Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00441974 |
This 48-week open-label study of local manufactured adefovir dipivoxil Tablet evaluates the efficacy and safety of adefovir 10mg once daily in Chinese subjects with compensated CHB. Primary endpoint is proportion of subjects achieving HBV DNA undetectable (<=1000 copies/mL by by Roche COBAS AMPLICOR HBV MONITOR Test) at week 48. Approximately 1250 patients will be recruited in 30 study centers in China. The subjects are offered 48 weeks of open label adefovir dipivoxil treatment, with assessments every three months, after with is a 12-week post study treatment follow-up prior to study completion.
Condition | Intervention | Phase |
---|---|---|
Chronic Hepatitis B |
Drug: adefovir dipivoxil |
Phase IV |
Study Type: | Interventional |
Study Design: | Non-Randomized, Open Label, Safety/Efficacy Study, Single Group Assignment, Treatment |
Official Title: | A 48-Week Multi-Centre, Open-Label, Local Phase IV Study to Demonstrate the Efficacy and Safety of Adefovir Dipivoxil Tablets (10mg) in Chinese Subjects With Compensated Chronic Hepatitis B |
Enrollment: | 1470 |
Study Start Date: | December 2006 |
Study Completion Date: | September 2008 |
Primary Completion Date: | September 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Single arm adefovir dipivoxil: Experimental
adefovir dipivoxil once daily orally 10 mg
|
Drug: adefovir dipivoxil
adefovir dipivoxil once daily one tablet 10mg orally
|
Ages Eligible for Study: | 16 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
China | |
GSK Investigational Site | |
Changsha, China, 410011 | |
GSK Investigational Site | |
Fuzhou, China, 350025 | |
GSK Investigational Site | |
Beijing, China, 100050 | |
GSK Investigational Site | |
Shanghai, China, 200025 | |
GSK Investigational Site | |
Shanghai, China, 200040 | |
GSK Investigational Site | |
Shanghai, China, 200433 | |
GSK Investigational Site | |
Beijing, China, 100011 | |
GSK Investigational Site | |
Chongqing, China, 400038 | |
GSK Investigational Site | |
Changsha, China, 410008 | |
GSK Investigational Site | |
Beijing, China, 100069 | |
GSK Investigational Site | |
Jinan, China, 250021 | |
GSK Investigational Site | |
Chongquin, China, 400038 | |
GSK Investigational Site | |
Beijing, China, 100044 | |
GSK Investigational Site | |
Shanghai, China, 200003 | |
GSK Investigational Site | |
Tianjin, China, 300192 | |
GSK Investigational Site | |
Shanghai, China, 200001 | |
China, Guangdong | |
GSK Investigational Site | |
Guangzhou, Guangdong, China, 510630 | |
GSK Investigational Site | |
Guangzhou, Guangdong, China, 510515 | |
China, Hubei | |
GSK Investigational Site | |
Wuhan, Hubei, China, 430030 | |
China, Jiangsu | |
GSK Investigational Site | |
Nanjing, Jiangsu, China, 210002 | |
GSK Investigational Site | |
Nanjing, Jiangsu, China, 210029 | |
GSK Investigational Site | |
Nanjing, Jiangsu, China, 210003 | |
China, Jilin | |
GSK Investigational Site | |
Changchun, Jilin, China, 130021 | |
China, Sichuan | |
GSK Investigational Site | |
Chengdu, Sichuan, China, 610041 | |
China, Zhejiang | |
GSK Investigational Site | |
Hangzhou, Zhejiang, China, 310009 |
Study Director: | GSK Clinical Trials | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | ADF108356 |
Study First Received: | February 28, 2007 |
Last Updated: | March 12, 2009 |
ClinicalTrials.gov Identifier: | NCT00441974 History of Changes |
Health Authority: | China: State Food and Drug Administration |
adefovir dipivoxil Chinese chronic hepatitis B compensated |
Liver Diseases Hepatitis, Chronic Hepatitis, Viral, Human Antiviral Agents Reverse Transcriptase Inhibitors Hepatitis Virus Diseases |
Digestive System Diseases Anti-Retroviral Agents Hepatitis B, Chronic Hepatitis B DNA Virus Infections Adefovir dipivoxil Adefovir |
Anti-Infective Agents Liver Diseases Molecular Mechanisms of Pharmacological Action Hepatitis, Chronic Hepatitis, Viral, Human Enzyme Inhibitors Hepadnaviridae Infections Antiviral Agents Pharmacologic Actions Reverse Transcriptase Inhibitors Hepatitis |
Virus Diseases Digestive System Diseases Anti-Retroviral Agents Therapeutic Uses Hepatitis B, Chronic Hepatitis B DNA Virus Infections Adefovir dipivoxil Adefovir Nucleic Acid Synthesis Inhibitors |